PAPP-A concentrations change in patients with gestational diabetes

Area of Science:

• Reproductive endocrinology and metabolism
• Maternal-fetal medicine
• Biochemical markers in pregnancy

Background:

• Pregnancy Associated Plasma Protein-A (PAPP-A) is a placental protein crucial for insulin-like growth factor (IGF) bioavailability, impacting fetal and placental growth.
• Previous studies suggest impaired PAPP-A levels in women who later develop gestational diabetes mellitus (GDM).
• The role of first-trimester biochemical markers in predicting GDM requires further elucidation.

Purpose of the Study:

• To investigate the association between gestational diabetes and glucose intolerance with maternal serum PAPP-A and free β-hCG concentrations during the first trimester.
• To determine if PAPP-A and fβ-hCG levels can serve as early indicators for GDM risk.

Main Methods:

• A cohort of 278 women with singleton pregnancies underwent first-trimester screening and oral glucose tolerance tests (OGTT).
• Participants were categorized into four groups based on OGTT results: Control, positive 50g OGTT/negative 100g OGTT, GDM, and single high glucose level.
• Serum concentrations of PAPP-A and free β-hCG were measured and compared across the defined groups.

Main Results:

• Women diagnosed with GDM exhibited significantly lower serum PAPP-A concentrations compared to the control group (p=0.015).
• No significant differences in maternal serum free β-hCG concentrations were observed among the study groups.
• The overall GDM incidence in the study population was 21.1%.

Conclusions:

• Significantly reduced first-trimester serum PAPP-A levels are associated with the development of gestational diabetes mellitus.
• First-trimester free β-hCG levels do not appear to be a reliable marker for GDM risk.
• Monitoring PAPP-A concentrations may offer potential for early GDM prediction, enabling timely interventions to protect fetal health.